Diabetes is the 4th leading cause of global annual deaths by disease affecting 246 million people worldwide and is expected to affect 380 million by 2025 with growing prevalence's in developing countries. Each year a further 7 million people develop diabetes, 50% of all diabetics are unaware of their condition, and 3.8 million annually.
Sulfonylureas:
Glimepiride (Amaryl)
Glipizide(Glucotrol/Glucotrol XL)
Glibenclamide (Glyburide, DiaBeta, Micronase)
Biguanides:
Metformin (Glucophage, Glucophage XR)
Sulfonylurea/Biguanide combination:
Glyburide and Metformin (Glucovance)
Alpha-glucosidase inhibitors:
Acarbose (Precose)
Miglitol (Glyset)
Thiazolidinediones:
Pioglitazone (Actos)
Rosiglitazone (Avandia)
Meglitinides:
Repaglinide (Prandin)
Nateglinide (Starlix)
Development of a optimized, safe, effective and affordable class of novel antidiabetic-prophylaxis and anti-diabetic umbelliferone derivatives (4-meythylumbelliferone).
BioMonde is focused on the prevention and management of Diabetes, and improving the viability and effectiveness of existing anti-diabetic treatments such as Glibenclamide and their adverse affects. As more than 50% of diabetes is not diagnosed, there is a need for a preventive therapy that is readily available and does not have adverse side effects. This is especially true of induced diabetes caused by HIV, drugs, cholesterol, and hypertension. Consequently, BioMonde's approach means that more diabetics and potential diabetic patients have access to effective healthcare.
Indicates that umbelliferone derivatives (4-meythylumbellierone) administered as a preventive or management therapy, with or without anti-diabetic Glibenclamide treatment improves several underlying symptoms associated with diabetes.
